FDA Approves Higher Dose of Wegovy in the US

• The 7.2 mg dose received priority review voucher for accelerated approval, representing the first GLP-1 treatment under the Commissioner's National Priority Voucher program
• Clinical results demonstrated 20.7% average weight loss with weekly administration, and approximately 33% of patients achieved 25% or greater weight reduction
• U.S. launch planned for April 2024 as a single-dose pen, while the UK already approved the higher dose administered as three separate injections

FDA Approves Higher Dose of Wegovy in the US

Key Development:

The U.S. Food and Drug Administration approved a higher 7.2 milligram dose of Novo Nordisk's blockbuster obesity drug Wegovy on March 19. This marks the first GLP-1 treatment approval under the FDA Commissioner's National Priority Voucher program, which granted priority review to expedite the approval process.

Clinical Results:

The approval was supported by clinical trial data showing patients receiving the 7.2 mg dose once weekly achieved:

• Average weight loss of 20.7%
• Approximately one in three patients experienced 25% or greater weight loss

The drug is indicated for reducing excess body weight and maintaining long-term weight reduction.

Market Launch:

Novo Nordisk plans to launch the higher-dose Wegovy in the U.S. in April, delivered via a single-dose pen. The higher dose has already received approval in the UK, where it is administered as three separate injections.

Market Implications:

This approval strengthens Novo Nordisk's competitive position in the rapidly growing obesity treatment market. The enhanced efficacy of the higher dose—with nearly one-third of patients achieving 25%+ weight loss—could expand the addressable patient population and drive additional revenue for the company's already successful Wegovy franchise.

The priority review designation underscores regulatory recognition of the drug's importance in addressing obesity, a major public health concern. The April U.S. launch timing positions Novo Nordisk to capture increased market share in the lucrative GLP-1 obesity treatment sector ahead of competitors.